ABEONA THERAPEUTICS INC. (ABEO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 24.81M USD | Liabilities, Current |
| Cash and equivalents | 56.23M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 9.39M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 5.92M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $24.81M | $56.23M | (m) | $9.39M | $5.92M | (m) |
| 2026-03-31 | (m) | $31.05M | $61.37M | (m) | $6.20M | $6.05M | (m) |
| 2025-12-31 | (m) | $29.57M | $78.44M | (m) | $6.15M | $5.49M | (m) |
| 2025-09-30 | (m) | $22.18M | $82.88M | (m) | (m) | $4.85M | (m) |
| 2025-06-30 | (m) | $34.52M | $163.53M | (m) | (m) | $2.69M | (m) |
| 2025-03-31 | (m) | $17.98M | $15.94M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $16.59M | $23.36M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $18.42M | $15.73M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $16.84M | $34.43M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.89M | $17.56M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $13.42M | $14.47M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $8.41M | $4.71M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $9.44M | $6.22M | (m) | $3.50M | (m) | (m) |
| 2023-03-31 | (m) | $7.42M | $4.68M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $7.78M | $14.22M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $12.60M | $5.73M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $13.69M | $6.13M | (m) | $1.00M | (m) | (m) |
| 2022-03-31 | (m) | $12.34M | $20.33M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $16.62M | $32.94M | (m) | $3.00M | (m) | (m) |
| 2021-09-30 | (m) | $26.47M | $43.78M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $41.87M | $27.18M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $40.84M | $14.27M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $41.96M | $12.60M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $38.74M | $8.42M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $37.56M | $14.54M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $36.61M | $40.16M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $38.70M | $129.26M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $20.24M | $47.92M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $25.54M | $42.61M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $21.42M | $25.92M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $20.35M | $18.75M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $10.33M | $33.60M | $78.63M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $5.78M | $49.99M | $69.85M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $6.45M | $132.00M | (m) | (m) | (m) | (m) |
| 2018-01-02 | (m) | $2.61M | (m) | (m) | (m) | (m) | (m) |
| 2018-01-01 | (m) | $2.39M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $5.61M | $137.75M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.64M | $56.52M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $4.22M | $58.30M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $6.07M | $63.21M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $8.30M | $69.14M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.51M | $31.18M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $8.71M | $34.30M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.64M | $37.40M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.48M | $40.14M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.57M | $43.28M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.92M | $30.41M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.24M | $7.95M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.90M | $11.52M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $12.62M | $165.00K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $11.17M | $55.00K | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $10.04M | $299.00K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $8.96M | $424.00K | (m) | (m) | $0.00 | (m) |
| 2013-09-30 | (m) | $8.01M | $899.00K | (m) | (m) | $0.00 | (m) |
| 2013-06-30 | (m) | $7.77M | $1.80M | (m) | (m) | $0.00 | (m) |
| 2013-03-31 | (m) | $7.75M | $50.00K | (m) | (m) | $150.00K | (m) |
| 2012-12-31 | (m) | $6.63M | $396.00K | (m) | (m) | $194.00K | (m) |
| 2012-09-30 | (m) | $8.99M | $106.00K | (m) | (m) | $236.00K | (m) |
| 2012-06-30 | (m) | $14.05M | $588.00K | (m) | (m) | $281.00K | (m) |
| 2012-03-31 | (m) | $12.90M | $1.36M | (m) | (m) | $97.00K | (m) |
| 2011-12-31 | (m) | $12.19M | $2.46M | (m) | (m) | $151.00K | (m) |
| 2011-09-30 | (m) | $14.27M | $1.35M | (m) | (m) | $192.00K | (m) |
| 2011-06-30 | (m) | $12.87M | $4.35M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $6.17M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $14.26M | $7.03M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $1.50M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $2.76M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $607.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |